Physiologically-based pharmacokinetic modelling of the 2-monthly regimen of long-acting injectable rilpivirine administered in pregnancy

被引：0
|
作者：
Atoyebi, Shakir [1 ]
Siccardi, Marco [1 ]
Waitt, Catriona [1 ]
机构：
[1] Univ Liverpool, Liverpool, England
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P0643
引用
收藏
页码：338 / 340
页数：3
相关论文
共 50 条
  • [31] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
    Santiago Moreno
    Antonio Rivero
    Pere Ventayol
    Vicenç Falcó
    Miguel Torralba
    Melanie Schroeder
    Victoria Neches
    Laura Amanda Vallejo-Aparicio
    Isaac Mackenzie
    Matthew Turner
    Cale Harrison
    Infectious Diseases and Therapy, 2023, 12 : 2039 - 2055
  • [32] Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data
    Gong, Jiachang
    Iacono, Lisa
    Iyer, Ramaswamy A.
    Humphreys, William G.
    Zheng, Ming
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (06) : 1335 - 1345
  • [33] Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study
    Parker, Ben
    Ward, Tom
    Hayward, Olivia
    Jacob, Ian
    Arthurs, Erin
    Becker, Debbie
    Anderson, Sarah-Jane
    Chounta, Vasiliki
    Van de Velde, Nicolas
    PLOS ONE, 2021, 16 (02):
  • [34] Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments
    Aparicio, Laura-Amanda Vallejo
    Garcia, Victoria Neches
    Hernandez-Novoa, Beatriz
    Casado, Gregorio
    Jodar, Ferran
    Pinel, Marco
    Velasco, Daniel Callejo
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [35] Outcomes for women receiving long-acting cabotegravir plus rilpivirine monthly and every two months: ATLAS-2M study Week 48 results
    Benn, P.
    Quercia, R.
    Hudson, K.
    Wang, Y.
    Chounta, V.
    Talarico, C.
    Ford, S.
    Cutrell, A.
    Margolis, D.
    Van Solingen-Ristea, R.
    Vanveggel, S.
    Van Eygen, V.
    Polli, J.
    de Ruiter, A.
    Smith, K.
    Spreen, W.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 28 - 29
  • [36] Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
    Marjie L. Hard
    Angela Y. Wehr
    Brian M. Sadler
    Richard J. Mills
    Lisa von Moltke
    European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 : 461 - 469
  • [37] Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil
    Hard, Marjie L.
    Wehr, Angela Y.
    Sadler, Brian M.
    Mills, Richard J.
    von Moltke, Lisa
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (04) : 461 - 469
  • [38] Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area
    Nguyen, Ngan M.
    Kavanagh, Rebecca
    Gozar, Martin
    Cabral, Danielle
    Goetz, Holly
    Cha, Agnes
    Mcgowan, Joseph P.
    Pao, Megan L.
    AIDS PATIENT CARE AND STDS, 2024, 38 (03) : 115 - 122
  • [39] Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling
    Zhou, Li
    Sharma, Pradeep
    Yeo, Karen Rowland
    Higashimori, Mitsuo
    Xu, Hongmei
    Al-Huniti, Nidal
    Zhou, Diansong
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 139
  • [40] Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
    Luis Gutiérrez‐Rojas
    Sergio Sánchez-Alonso
    Marta García Dorado
    Paola M. López Rengel
    CNS Drugs, 2022, 36 : 517 - 527
12345